Head & Neck/Thyroid Cancers
From the Journals
New investigational helmet device shrinks glioblastoma
A case report of a 53-year-old man describes using an “Oncomagnetic Device” that reduced the size of a tumor after one month of treatment.
Latest News
More children with high-risk brain cancer now surviving
Conference Coverage
Adjuvant capecitabine shown a less punishing option after NPC chemoradiation
Conference Coverage
Cabozantinib gains ground for salvage in differentiated thyroid cancer
Conference Coverage
New drug toripalimab improves survival in nasopharyngeal cancer
The drug is a monoclonal antibody that blocks programmed cell dealth protein 1 (PD-1).
Conference Coverage
Photobiomodulation reduced acute radiodermatitis severity in head and neck cancer patients
“Future studies should focus on randomized controlled study designs with well-described and complete PBMT parameters in a larger and more diverse...
From the Journals
Study supports intensifying chemoradiotherapy for head and neck cancer
Intensifying chemoradiotherapy appeared to improve outcomes in locally advanced head and neck cancer.
Clinical Insights
The power and promise of social media in oncology
Dr. Alan Lyss describes a recent presentation on the role of social media in oncology.
From the Journals
Hyperprogression on immunotherapy: When outcomes are much worse
From the Journals
Lobaplatin deemed ‘promising alternative’ to cisplatin in nasopharyngeal carcinoma
A lobaplatin-based regimen was as effective as a cisplatin-based regimen in a phase 3 trial.
Conference Coverage
Personalized cancer vaccine shows early promise across tumor types
The vaccine consists of patient-specific synthetic neoantigen peptides and is given to patients in the adjuvant setting.